ISSN 2515-8260
 

Research Article 


Small molecule PAI-1 functional inhibitor attenuates vascular smooth muscle cell migration and survival: Implications for the therapy of vascular disease

Tessa M. Simone, Paul J. Higgins.

Abstract
Focal points

Bedside

Targeted pharmacologic disruption of PAI-1 function with small molecule inhibitors may have general applicability for the treatment of fibroproliferative disorders, in general, and vascular disease, in particular. The development orally compatible drugs would likely simplify delivery and patient compliance.


Benchside

It is apparent that PAI-1 is a multi-functional SERPIN, affecting such diverse physiological and pathophysiological processes as smooth muscle cell growth, migration, survival and pericellular proteolysis activity. Clearly, PAI-1 functional blockade has widespread clinical implications that are not restricted to one aspect of the tissue response to injury.


Industry

The original small molecule panel of PAI-1 inhibitors derived from a collaboration between basic scientists and, largely, cardiovascular disease-oriented medical chemists as well as pharmaceutical investigators. This collegial relationship is expected to expand as it is evident that PAI-1 inhibition has generally utility in the treatment of cardiovascular diseases, tissue fibrosis (in particular, the renal and pulmonary systems) and cancer.

Key words: Vascular diseasePAI-1SERPINPericellular proteolysisTiplaxtininVascular smooth muscle cellsMigrationApoptosis


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Tessa M. Simone
Articles by Paul J. Higgins
on Google
on Google Scholar

How to Cite this Article
Pubmed Style

Tessa M. Simone, Paul J. Higgins. Small molecule PAI-1 functional inhibitor attenuates vascular smooth muscle cell migration and survival: Implications for the therapy of vascular disease. EJMCM. 2014; 2(1): 16-19.


Web Style

Tessa M. Simone, Paul J. Higgins. Small molecule PAI-1 functional inhibitor attenuates vascular smooth muscle cell migration and survival: Implications for the therapy of vascular disease. http://www.ejmcm.com/?mno=116528 [Access: June 19, 2020].


AMA (American Medical Association) Style

Tessa M. Simone, Paul J. Higgins. Small molecule PAI-1 functional inhibitor attenuates vascular smooth muscle cell migration and survival: Implications for the therapy of vascular disease. EJMCM. 2014; 2(1): 16-19.



Vancouver/ICMJE Style

Tessa M. Simone, Paul J. Higgins. Small molecule PAI-1 functional inhibitor attenuates vascular smooth muscle cell migration and survival: Implications for the therapy of vascular disease. EJMCM. (2014), [cited June 19, 2020]; 2(1): 16-19.



Harvard Style

Tessa M. Simone, Paul J. Higgins (2014) Small molecule PAI-1 functional inhibitor attenuates vascular smooth muscle cell migration and survival: Implications for the therapy of vascular disease. EJMCM, 2 (1), 16-19.



Turabian Style

Tessa M. Simone, Paul J. Higgins. 2014. Small molecule PAI-1 functional inhibitor attenuates vascular smooth muscle cell migration and survival: Implications for the therapy of vascular disease. European Journal of Molecular & Clinical Medicine, 2 (1), 16-19.



Chicago Style

Tessa M. Simone, Paul J. Higgins. "Small molecule PAI-1 functional inhibitor attenuates vascular smooth muscle cell migration and survival: Implications for the therapy of vascular disease." European Journal of Molecular & Clinical Medicine 2 (2014), 16-19.



MLA (The Modern Language Association) Style

Tessa M. Simone, Paul J. Higgins. "Small molecule PAI-1 functional inhibitor attenuates vascular smooth muscle cell migration and survival: Implications for the therapy of vascular disease." European Journal of Molecular & Clinical Medicine 2.1 (2014), 16-19. Print.



APA (American Psychological Association) Style

Tessa M. Simone, Paul J. Higgins (2014) Small molecule PAI-1 functional inhibitor attenuates vascular smooth muscle cell migration and survival: Implications for the therapy of vascular disease. European Journal of Molecular & Clinical Medicine, 2 (1), 16-19.